Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 18, 2021BloodOpen Access

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

View Full Paper
Ask AI
Bookmark
Share

Authors

DRDelphine RéaInstitut BergoniéMMMichael J. MauroMemorial Sloan Kettering Cancer CenterCBCarla BoquimpaniHemorio

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Réa et al. (2021) studied this question.

synapsesocial.com/papers/69d9ac8f387cf706986850dahttps://doi.org/10.1182/blood.2020009984
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia2019 · 42 citations
  2. 2Moving treatment-free remission into mainstream clinical practice in CML2016 · 322 citations
  3. 3Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants2017 · 341 citations
  4. 4Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors2020 · 107 citations
  5. 5Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure2019 · 481 citations